Sen S, Mookerjee R P, Davies N A, Williams R, Jalan R
Institute of Hepatology, University College London Medical School and University College London Hospitals, UK.
Aliment Pharmacol Ther. 2002 Dec;16 Suppl 5:32-8. doi: 10.1046/j.1365-2036.16.s5.5.x.
In recent years different artificial liver support systems are being developed for use in patients with acute decompensation of chronic liver disease or acute liver failure. The molecular adsorbents recirculating system (MARS), a device in which patient's blood is dialysed across an albumin-impregnated membrane against a recirculated albumin-containing solution, seems to be effective in removing albumin-bound toxins, such as fatty acids, bile acids and bilirubin. Although the clinical experience with MARS is scarce, some pilot studies have reported its effectiveness at improving liver function and hepatic encephalopathy in patients with acute decompensation of chronic liver disease, and renal function in patients with hepatorenal syndrome type I. Data regarding MARS experience in acute liver failure and in primary graft dysfunction are encouraging but limited. Its real usefulness in these settings is, at present, under evaluation in randomized controlled clinical trials.
近年来，不同的人工肝支持系统正在被研发用于患有慢性肝病急性失代偿或急性肝衰竭的患者。分子吸附再循环系统（MARS）是一种通过患者血液透过浸有白蛋白的膜与再循环的含白蛋白溶液进行透析的装置，似乎在清除与白蛋白结合的毒素（如脂肪酸、胆汁酸和胆红素）方面有效。尽管MARS的临床经验较少，但一些初步研究报告了其在改善慢性肝病急性失代偿患者的肝功能和肝性脑病以及I型肝肾综合征患者的肾功能方面的有效性。关于MARS在急性肝衰竭和原发性移植肝无功能方面的经验数据令人鼓舞，但有限。目前，其在这些情况下的实际效用正在随机对照临床试验中进行评估。
